Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Bruce D. Steel C.F.A. |
Contact Details
Address: 2223 Avenida De La Playa, Suite 105 La Jolla, California 92037 United States | |
| Phone | (858) 412-5302 |
| Website | equilliumbio.com |
Stock Details
| Ticker Symbol | EQ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001746466 |
| CUSIP Number | 29446K106 |
| ISIN Number | US29446K1060 |
| Employer ID | 82-1554746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Mark Bradbury | Executive Chairman |
| Bruce D. Steel C.F.A. | Co-Founder, President, Chief Executive Officer and Director |
| Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President and Chief Operating Officer |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer and Director |
| Jason A. Keyes | Chief Financial Officer |
| Penny Tom | Senior Vice President of Finance and Principal Accounting Officer |
| Michael Moore | Vice President of Investor Relations and Corporate Communications |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development |
| Joel M. Rothman | Chief Development Officer |
| Dr. Maple Fung M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |